LENZ Therapeutics (LENZ) Competitors $28.22 +0.06 (+0.21%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$27.31 -0.91 (-3.22%) As of 08:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LENZ vs. MTSR, VKTX, AKRO, ALVO, CPRX, CRNX, SRRK, MRUS, MOR, and PTGXShould you be buying LENZ Therapeutics stock or one of its competitors? The main competitors of LENZ Therapeutics include Metsera (MTSR), Viking Therapeutics (VKTX), Akero Therapeutics (AKRO), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), Crinetics Pharmaceuticals (CRNX), Scholar Rock (SRRK), Merus (MRUS), MorphoSys (MOR), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. LENZ Therapeutics vs. Metsera Viking Therapeutics Akero Therapeutics Alvotech Catalyst Pharmaceuticals Crinetics Pharmaceuticals Scholar Rock Merus MorphoSys Protagonist Therapeutics Metsera (NASDAQ:MTSR) and LENZ Therapeutics (NASDAQ:LENZ) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, community ranking, risk and valuation. Does the MarketBeat Community favor MTSR or LENZ? LENZ Therapeutics received 11 more outperform votes than Metsera when rated by MarketBeat users. CompanyUnderperformOutperformMetseraOutperform Votes4100.00% Underperform VotesNo VotesLENZ TherapeuticsOutperform Votes15100.00% Underperform VotesNo Votes Do analysts prefer MTSR or LENZ? Metsera presently has a consensus target price of $47.00, indicating a potential upside of 67.56%. LENZ Therapeutics has a consensus target price of $46.60, indicating a potential upside of 65.13%. Given Metsera's higher possible upside, equities analysts clearly believe Metsera is more favorable than LENZ Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metsera 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Do insiders & institutionals have more ownership in MTSR or LENZ? 54.3% of LENZ Therapeutics shares are held by institutional investors. 38.4% of LENZ Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has preferable valuation and earnings, MTSR or LENZ? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetseraN/AN/AN/AN/AN/ALENZ TherapeuticsN/AN/A-$124.65M-$1.77-15.94 Is MTSR or LENZ more profitable? Metsera's return on equity of 0.00% beat LENZ Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MetseraN/A N/A N/A LENZ Therapeutics N/A -58.48%-55.50% Does the media prefer MTSR or LENZ? In the previous week, LENZ Therapeutics had 3 more articles in the media than Metsera. MarketBeat recorded 3 mentions for LENZ Therapeutics and 0 mentions for Metsera. LENZ Therapeutics' average media sentiment score of 1.65 beat Metsera's score of 0.00 indicating that LENZ Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Metsera Neutral LENZ Therapeutics Very Positive SummaryLENZ Therapeutics beats Metsera on 8 of the 11 factors compared between the two stocks. Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LENZ vs. The Competition Export to ExcelMetricLENZ TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$794.28M$2.93B$5.33B$8.39BDividend YieldN/A1.63%5.21%4.10%P/E Ratio-15.9431.1826.7719.70Price / SalesN/A398.78393.27122.35Price / CashN/A168.6838.2534.62Price / Book1.283.236.774.50Net Income-$124.65M-$72.35M$3.23B$248.22M7 Day Performance5.26%2.49%0.43%-0.80%1 Month Performance4.71%2.45%9.07%11.52%1 Year Performance79.52%-24.98%18.57%8.99% LENZ Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LENZLENZ Therapeutics1.9263 of 5 stars$28.22+0.2%$46.60+65.1%+53.3%$794.28MN/A-15.94110Gap UpMTSRMetseraN/A$28.96-1.9%$47.00+62.3%N/A$3.10BN/A0.0081Gap DownVKTXViking Therapeutics4.4196 of 5 stars$27.50-3.3%$87.15+216.9%-56.0%$3.09BN/A-27.5020Positive NewsAKROAkero Therapeutics3.8084 of 5 stars$38.14-1.9%$82.33+115.9%+138.9%$3.04BN/A-10.1730ALVOAlvotech1.7535 of 5 stars$10.07-3.7%$18.00+78.7%-29.0%$3.04B$585.60M-5.444CPRXCatalyst Pharmaceuticals4.6118 of 5 stars$24.63+1.1%$32.29+31.1%+49.4%$3.00B$534.65M20.8780Positive NewsCRNXCrinetics Pharmaceuticals3.5443 of 5 stars$30.95-0.9%$73.00+135.9%-40.4%$2.90B$760,000.00-8.30210Positive NewsSRRKScholar Rock3.9788 of 5 stars$30.16-1.3%$42.67+41.5%+160.1%$2.86B$33.19M-12.83140MRUSMerus3.2305 of 5 stars$41.36-0.5%$84.54+104.4%-4.1%$2.86B$54.73M-10.4737Positive NewsOptions VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730PTGXProtagonist Therapeutics3.3858 of 5 stars$45.57+2.4%$65.44+43.6%+44.8%$2.82B$207.80M17.13120Positive News Related Companies and Tools Related Companies MTSR Competitors VKTX Competitors AKRO Competitors ALVO Competitors CPRX Competitors CRNX Competitors SRRK Competitors MRUS Competitors MOR Competitors PTGX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LENZ) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
